AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35759555 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg/Acetaminophen 1000 mg
Number of subjects: 250
Study 35759555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 33829946 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow chest compression (SCC) after exercise
Number of subjects: 40
Study 33829946 — intervention group
Group type: COMPARATOR
Intervention: Control (rest after exercise)
Number of subjects: 40
Study 33829946 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow chest compression (SCC) responders
Number of subjects: 40
Study 32796574 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimising the Health Extension Program intervention
Number of subjects: 52
Study 32796574 — intervention group
Group type: COMPARATOR
Intervention: N/A (Control group)
Number of subjects: 52
Study 32796574 — intervention group
Group type: EXPERIMENTAL
Intervention: N/A (Intervention activities)
Number of subjects: 52
Study 34402887 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab SC
Number of subjects: 410
Study 34402887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study 34493820 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular-matched treatment
Number of subjects: 87
Study 34493820 — intervention group
Group type: COMPARATOR
Intervention: Best investigator's choice (standard therapy)
Number of subjects: 87
Study 34501940 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS (transcutaneous electrical stimulation)
Number of subjects: 48
Study 34501940 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 33486749 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrx approach (minimally invasive transmuscular approach using a tubular retractor system)
Number of subjects: 227
Study 33486749 — intervention group
Group type: COMPARATOR
Intervention: Conventional microsurgical approach (CM)
Number of subjects: 227
Study 33486749 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrx approach
Number of subjects: 227
Study 32762446 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Number of subjects: 0
Study 32762446 — intervention group
Group type: COMPARATOR
Intervention: Conventional 12-month DAPT
Number of subjects: 0
Study 35311719 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional trunk training (3 days/week for 8 weeks)
Number of subjects: 20
Study 35311719 — intervention group
Group type: COMPARATOR
Intervention: Trunk stabilization and balance exercises (control group)
Number of subjects: 20
Study 35311719 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional trunk training
Number of subjects: 20
Study 32911138 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Number of subjects: 24
Study 32911138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 35698215 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthroposophic supportive treatment (AST)
Number of subjects: 288
Study 35698215 — intervention group
Group type: COMPARATOR
Intervention: Control (no anthroposophic base medication)
Number of subjects: 288
Study 35698215 — intervention group
Group type: COMPARATOR
Intervention: AST and Control
Number of subjects: 288
Study 33509035 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention
Number of subjects: 44
Study 33509035 — intervention group
Group type: COMPARATOR
Intervention: Education only (control group)
Number of subjects: 44
Study 34998436 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving study results (summary of study results via letter)
Number of subjects: 304
Study 32959586 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger-separated moxibustion and Chinese herbal medicine atomization
Number of subjects: 90
Study 32959586 — intervention group
Group type: COMPARATOR
Intervention: Ambroxol hydrochloride oral solution and compound methoxynamine capsules, with salbutamol aerosol
Number of subjects: 90
Study 36084899 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT), details on dosage and duration not specified
Number of subjects: 0
Study 36084899 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT, remotely-delivered intervention
Number of subjects: 0
Study 33250326 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary group pain program
Number of subjects: 56
Study 34643650 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (125 mg weekly from weeks 12 to 39)
Number of subjects: 108
Study 34643650 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab (45 mg or 90 mg at weeks 0 and 4, then at weeks 16 and 28)
Number of subjects: 108
Study 34643650 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 108
Study 34643650 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 108
Study 34643650 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 108
Study 32332962 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine
Number of subjects: 156
Study 32332962 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 156
Study 32332962 — intervention group
Group type: COMPARATOR
Intervention: Mepivacaine
Number of subjects: 156
Study 35775789 — intervention group
Group type: EXPERIMENTAL
Intervention: GLB-TBI intervention (12-month, 22-session program)
Number of subjects: 54
Study 35775789 — intervention group
Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 54
Study 35775789 — intervention group
Group type: EXPERIMENTAL
Intervention: GLB-TBI compliant group (≥80% attendance; ≥85% self-monitoring; n = 10)
Number of subjects: 54
Study 35775789 — intervention group
Group type: EXPERIMENTAL
Intervention: GLB-TBI noncompliant group (n = 17)
Number of subjects: 54
Study 35775789 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (n = 27)
Number of subjects: 54
Study 32911979 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged excision with circumferential margin control (SECMC)
Number of subjects: 102
Study 32321764 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 IFCN criteria in sensor space
Number of subjects: 100
Study 32321764 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis in source space
Number of subjects: 100
Study 32321764 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert scoring
Number of subjects: 100
Study 35961647 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrument-Assisted Soft Tissue Mobilization (IASTM)
Number of subjects: 33
Study 35961647 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Cupping (TC)
Number of subjects: 33
Study 34090504 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (Stromectol®‐0.15 mg/kg)
Number of subjects: 0
Study 34090504 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34090504 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 0
Study 36162006 — intervention group
Group type: EXPERIMENTAL
Intervention: Instagram posts
Number of subjects: 1000
Study 36162006 — intervention group
Group type: EXPERIMENTAL
Intervention: Twitter posts
Number of subjects: 1000
Study 34225517 — intervention group
Group type: EXPERIMENTAL
Intervention: MDT treatment
Number of subjects: 60
Study 34225517 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment
Number of subjects: 60
Study 36274662 — intervention group
Group type: EXPERIMENTAL
Intervention: Malva Sylvestris cream applied twice a day for up to 14 days
Number of subjects: 60
Study 36274662 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 60
Study 33646303 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose decitabine (15 mg/m2 daily IV for 3 consecutive days) plus recombinant human thrombopoietin (300 U/kg daily)
Number of subjects: 91
Study 33646303 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine alone
Number of subjects: 91
Study 33646303 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 91
Study 33646303 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose decitabine
Number of subjects: 91
Study 32534942 — intervention group
Group type: EXPERIMENTAL
Intervention: SCORE chart
Number of subjects: 6811
Study 32534942 — intervention group
Group type: COMPARATOR
Intervention: High and very high-risk categories identified by SCORE
Number of subjects: 6811
Study 34232115 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-focused brief therapy (SFBT)
Number of subjects: 50
Study 34232115 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 50
Study 33853071 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental imagery condition
Number of subjects: 60
Study 33853071 — intervention group
Group type: COMPARATOR
Intervention: Standard repeated encoding condition
Number of subjects: 60
Study 35637845 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-moxibustion combined with rehabilitation training (RHT)
Number of subjects: 150
Study 35637845 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture-moxibustion alone
Number of subjects: 150
Study 34130387 — intervention group
Group type: COMPARATOR
Intervention: Single-dart anesthesia induction protocol
Number of subjects: 14
Study 34130387 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged two-dart anesthesia induction protocol
Number of subjects: 14
Study 34697392 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 949
Study 34697392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 949
Study 36305354 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg every 2 weeks (q2w)
Number of subjects: 0
Study 36305354 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg every 2 weeks (q2w)
Number of subjects: 0
Study 36305354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33241297 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 27
Study 33241297 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 27
Study 35277168 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide treatment
Number of subjects: 40
Study 35277168 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle counseling
Number of subjects: 40
Study 35277168 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Gal-3 levels
Number of subjects: 40
Study 35277168 — intervention group
Group type: EXPERIMENTAL
Intervention: Gal-3 levels
Number of subjects: 40
Study 35277168 — intervention group
Group type: COMPARATOR
Intervention: Comparison of baseline sST2 levels
Number of subjects: 40
Study 33801514 — intervention group
Group type: EXPERIMENTAL
Intervention: Disaster prevention education with weekly exercise
Number of subjects: 97
Study 33801514 — intervention group
Group type: COMPARATOR
Intervention: Traditional exercise education with weekly exercise
Number of subjects: 97
Study 32515413 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX)
Number of subjects: 180
Study 32515413 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential Oils (EO)
Number of subjects: 180
Study 32515413 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetylpyridinium Chloride (CPC)
Number of subjects: 180
Study 32515413 — intervention group
Group type: COMPARATOR
Intervention: Negative Control
Number of subjects: 180
Study 34271146 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural Language Processing (NLP)
Number of subjects: 435
Study 34271146 — intervention group
Group type: COMPARATOR
Intervention: Manual chart review
Number of subjects: 435
Study 33515331 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid-brace treatment
Number of subjects: 225
Study 33515331 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent vertebral fractures
Number of subjects: 225
Study 33515331 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS) for low back pain
Number of subjects: 225
Study 33515331 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life and Function Scores
Number of subjects: 225
Study 33515331 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual incidence of subsequent vertebral fracture
Number of subjects: 225
Study 33515331 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to subsequent fractures
Number of subjects: 225
Study 35283439 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat messaging with daily individualized guidance
Number of subjects: 150
Study 35283439 — intervention group
Group type: COMPARATOR
Intervention: Routine guidance only
Number of subjects: 150
Study 33686683 — intervention group
Group type: EXPERIMENTAL
Intervention: Z-BUF-RL (Ringer's lactate)
Number of subjects: 90
Study 33686683 — intervention group
Group type: EXPERIMENTAL
Intervention: Z-BUF-R (Ringer's)
Number of subjects: 90
Study 33686683 — intervention group
Group type: EXPERIMENTAL
Intervention: Z-BUF-NS (Normal saline)
Number of subjects: 90
Study 36197213 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training with intensity controlled by biometric data (heart rate or RPE)
Number of subjects: 55
Study 36197213 — intervention group
Group type: COMPARATOR
Intervention: Robot-assisted gait training with intensity controlled by therapist's subjective judgment
Number of subjects: 55
Study 34519439 — intervention group
Group type: COMPARATOR
Intervention: BCAA (2×7 g/day)
Number of subjects: 36
Study 34519439 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine (2×7 g/day)
Number of subjects: 36
Study 32871891 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU of Vitamin D daily for 15 weeks
Number of subjects: 150
Study 32871891 — intervention group
Group type: COMPARATOR
Intervention: 200 IU of Vitamin D daily for 15 weeks
Number of subjects: 150
Study 35238614 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebotomy group (500 mL bloodletting at baseline and after 6 weeks)
Number of subjects: 53
Study 35238614 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 53
Study 35238614 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebotomy group
Number of subjects: 53
Study 35238614 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study 33448139 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum biochemical indexes (ALP, TP, Glu)
Number of subjects: 190
Study 33448139 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor markers (AFP, CA 125, CA199, HE4)
Number of subjects: 190
Study 33448139 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokines (VEGF, TNF‐α, IL‐6, sflt‐1, MCP‐1)
Number of subjects: 190
Study 32442523 — intervention group
Group type: EXPERIMENTAL
Intervention: sIPV-bOPV-bOPV (1sIPV+2bOPV group)
Number of subjects: 528
Study 32442523 — intervention group
Group type: EXPERIMENTAL
Intervention: sIPV-sIPV-bOPV (2sIPV+1bOPV group)
Number of subjects: 528
Study 32442523 — intervention group
Group type: EXPERIMENTAL
Intervention: sIPV-sIPV-sIPV (3sIPV group)
Number of subjects: 528
Study 35314636 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-based modified Lund-Mackay score (VMLMs)
Number of subjects: 50
Study 35314636 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Lund-Mackay score (TLMs)
Number of subjects: 50
Study 35314636 — intervention group
Group type: EXPERIMENTAL
Intervention: SNOT-22
Number of subjects: 50
Study 35314636 — intervention group
Group type: COMPARATOR
Intervention: Semi-supervised learning with convolutional neural networks
Number of subjects: 50
Study 34384991 — intervention group
Group type: EXPERIMENTAL
Intervention: AS reduction intervention
Number of subjects: 118
Study 34384991 — intervention group
Group type: COMPARATOR
Intervention: Repeated contact control condition
Number of subjects: 118
Study 35795713 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 as second dose (interventional group)
Number of subjects: 664
Study 35795713 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaccine initially, then BNT162b2 as second dose)
Number of subjects: 664
Study 34316173 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurogol syrup (a combination of valerian and lemon balm) with quetiapine, 5 mL every 12 hours for five consecutive days
Number of subjects: 53
Study 34316173 — intervention group
Group type: COMPARATOR
Intervention: Placebo with quetiapine, 5 mL every 12 hours for five consecutive days
Number of subjects: 53
Study 34316173 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurogol syrup (a combination of valerian and lemon balm) with quetiapine
Number of subjects: 53
Study 34316173 — intervention group
Group type: COMPARATOR
Intervention: Placebo with quetiapine
Number of subjects: 53
Study 32815405 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermal/Epidermal Substitute (Nevelia)
Number of subjects: 15
Study 32815405 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (Control Group)
Number of subjects: 15
Study 36175996 — intervention group
Group type: EXPERIMENTAL
Intervention: e-coachER intervention
Number of subjects: 450
Study 36175996 — intervention group
Group type: COMPARATOR
Intervention: ERS alone
Number of subjects: 450
Study 33058419 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic Aligners (OA)
Number of subjects: 39
Study 33058419 — intervention group
Group type: COMPARATOR
Intervention: Fixed Appliance (FA)
Number of subjects: 39
Study 32609946 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high-frequency percussive ventilation (nHFPV)
Number of subjects: 49
Study 32609946 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (nCPAP)
Number of subjects: 49
Study 35067340 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite of all-cause death or unplanned cardiovascular hospitalization within 30 days of presentation
Number of subjects: 0
Study 33934070 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab monotherapy (TCZm)
Number of subjects: 452
Study 33934070 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model on bDMARDm patients
Number of subjects: 452
Study 33934070 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended variable set with regularization
Number of subjects: 452
Study 32646823 — intervention group
Group type: EXPERIMENTAL
Intervention: PACE Steps to Success program (1-year train-the-trainer program for palliative care integration)
Number of subjects: 551
Study 35397289 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat infusion of autologous bone marrow
Number of subjects: 6
Study 33361473 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention (Group Lifestyle Balance Program)
Number of subjects: 322
Study 33361473 — intervention group
Group type: COMPARATOR
Intervention: Delayed-delivery intervention (control)
Number of subjects: 322
Study 35451612 — intervention group
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTATATE treatment at 7.4 GBq at 10 ± 2-week intervals until a predefined radiation dose to the kidneys was reached.
Number of subjects: 96
Study 35451612 — intervention group
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTATATE treatment
Number of subjects: 96
Study 33306679 — intervention group
Group type: EXPERIMENTAL
Intervention: Primed with a question about COVID-19
Number of subjects: 200
Study 33306679 — intervention group
Group type: COMPARATOR
Intervention: No prior contact (Control)
Number of subjects: 200
Study 33947374 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic supportive psychotherapy (SPSP)
Number of subjects: 308
Study 33947374 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 308
Study 33947374 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing the initial treatment with the same therapist
Number of subjects: 308
Study 33947374 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing the initial treatment with another therapist
Number of subjects: 308
Study 33947374 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing the other type of treatment with another therapist
Number of subjects: 308
Study 33947374 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic alliance, treatment integrity, and therapist allegiance
Number of subjects: 308
Study 33386040 — intervention group
Group type: EXPERIMENTAL
Intervention: PRF adjunct (PRF group, PG)
Number of subjects: 40
Study 33386040 — intervention group
Group type: COMPARATOR
Intervention: Extraction therapy only (spontaneous healing group, SHG)
Number of subjects: 40
Study 36162789 — intervention group
Group type: EXPERIMENTAL
Intervention: High pain group (observed model expressing higher pain scores)
Number of subjects: 0
Study 36162789 — intervention group
Group type: COMPARATOR
Intervention: Low pain group (control condition, observed model expressing lower pain scores)
Number of subjects: 0
Study 33982141 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT) 24 IU twice daily for 4 weeks
Number of subjects: 95
Study 33982141 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 95
Study 33202849 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based social intervention program (12-week meditation training)
Number of subjects: 0
Study 36005910 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal radial approach
Number of subjects: 250
Study 36005910 — intervention group
Group type: COMPARATOR
Intervention: Conventional radial approach
Number of subjects: 250
Study 33627708 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 minutes of vigorous exercise at 60% max
Number of subjects: 0
Study 32936872 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrefined carbohydrate diet
Number of subjects: 11
Study 32936872 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple carbohydrate diet
Number of subjects: 11
Study 32936872 — intervention group
Group type: COMPARATOR
Intervention: All diets
Number of subjects: 11
Study 35675275 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-minutes morning light treatment per day for four weeks
Number of subjects: 66
Study 35675275 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minutes morning light treatment per day for four weeks
Number of subjects: 66
Study 35675275 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-minutes morning light treatment per day for four weeks
Number of subjects: 66
Study 33115965 — intervention group
Group type: EXPERIMENTAL
Intervention: LCT/MCT propofol
Number of subjects: 129
Study 33115965 — intervention group
Group type: COMPARATOR
Intervention: LCT propofol
Number of subjects: 129